Drug Type Gene therapy |
Synonyms MQ 710, MQ-710 |
Target |
Action modulators |
Mechanism Flt3L modulators(Fms-related tyrosine kinase 3 ligand modulators), OX40L modulators(Tumor necrosis factor ligand superfamily member 4 modulators), Gene transference(Gene transference) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced cancer | Phase 1 | United States | 04 May 2023 | |
| Basal Cell Carcinoma | Phase 1 | United States | 04 May 2023 | |
| BRAF V600 mutation-positive Melanoma | Phase 1 | United States | 04 May 2023 | |
| Cutaneous Squamous Cell Carcinoma | Phase 1 | United States | 04 May 2023 | |
| Extramammary Paget Disease | Phase 1 | United States | 04 May 2023 | |
| Hemangiosarcoma | Phase 1 | United States | 04 May 2023 | |
| Kaposi Sarcoma | Phase 1 | United States | 04 May 2023 | |
| Merkel Cell Carcinoma | Phase 1 | United States | 04 May 2023 | |
| Neoplasm Metastasis | Phase 1 | United States | 04 May 2023 | |
| Refractory Cancer | Phase 1 | United States | 04 May 2023 |





